ResearcherFeist-Weiller Cancer CenterNo recent work listed

Roger H. Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0718-7376; OpenAlex author ID A5057603642. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper

Papers 2

Immunocompetent orthotopic pancreatic cancer murine model: a step in the right direction. First author DOI 10.1016/j.jss.2011.11.1011 ↗
Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model. Co-author DOI 10.1016/j.surg.2012.05.040 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Quyen D. Chu · 2 shared papers, 2012–2013 · strength 0.11
- Paper Immunocompetent orthotopic pancreatic cancer murine model: a step in the right direction. DOI 10.1016/j.jss.2011.11.1011 ↗
- Paper Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model. DOI 10.1016/j.surg.2012.05.040 ↗
James Michael Mathis · 1 shared paper, 2012 · strength 0.03
- Paper Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model. DOI 10.1016/j.surg.2012.05.040 ↗
David Terry Curiel · 1 shared paper, 2012 · strength 0.03
- Paper Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model. DOI 10.1016/j.surg.2012.05.040 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.